Putting Science to Work

Archives / 2016 / January

  • Syngene Q3 profit jumps 31% to Rs 59 cr.

    Business Standard-21/01/2016. Syngene reported a 31% jump in third quarter profits to Rs 59 crore and 23% growth in revenues to Rs 281 crore on improved business from its global clients to help build new drug discovery.

  • India has 'natural potential to grow' in CRO space, says Syngene CEO

    Outsourcing Pharma-14/01/2016. An exclusive interview with Peter Bains- CEO ,Syngene International Ltd -

  • Syngene appoints Jonathan Hunt as CEO-designate.

    Business Today-05/01/2016. Syngene appoints Jonathan Hunt as CEO-designate. Mr Hunt to take charge post retirement of current CEO Peter Bains. Mr Bains will continue as a member of the Syngene Board.

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget